Artthur M. Pappas
Founder, CEO & Managing General Partner @ Pappas Ventures
Durham, United States
Artthur M. Pappas is a Series A investor at Pappas Ventures in Durham focused on Biotechnology and Pharmaceutical. Arthur M. Pappas, MBA, founder and managing partner of the Research Triangle Park venture capital firm Pappas Ventures, has been elected chairman of the North Carolina Biotechnology Center's Board of Directors.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Artthur M. Pappas invests in
BiotechnologyPharmaceuticalHealth CareBiopharmaFashion
Stages Artthur M. Pappas invests in
Series ASeries BSeries DSeedSeries C
Countries Artthur M. Pappas invests in
United States
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (58%)
- Pharmaceutical 5 (42%)
- Health Care 4 (33%)
- Biopharma 2 (17%)
- Fashion 1 (8%)
Stage
- Series A 2 (17%)
- Series B 2 (17%)
- Series D 2 (17%)
- Seed 1 (8%)
- Series C 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Blank Label is an online custom shirt-maker that designs classic, custom-made menswear and delivers it to clients with a fit guarantee in as soon as 7 days. It has been highly rated by the Washington Post, and has received features from The New York Times, The Wall Street Journal, MSNBC, and more. From classic white shirts to indigo chambrays,four-season wool suits to corduroy pants, each fabric of Blank Label is handcut and made to clients’ personal, preferred size.Blank Label operates an online store, and its pattern room retail is located at downtown Boston. | $1.1M / Seed / Apr 23, 2015 | ||
| Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $21M / Series B / Mar 05, 2015 | ||
| Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California. | $5M / Series B / Apr 01, 2013 | ||
| CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $30.5M / Private Equity / Jul 01, 2012 | ||
| CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for thetreatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina. | $4.6M / Series D / Feb 03, 2012 | ||
| CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $60M / Private Equity / May 11, 2011 | ||
| Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. | $45M / Series F / Feb 14, 2011 | ||
| TyRx engages in the design, development, and commercialization of resorbable polymeric biomaterials. It offers PIVIT CRM, a mesh based pouch, which contains antibacterial agents to help provide protection from microbial colonization of the generator or defibrillator during and immediately after surgical implant. The company also provides AIGISRxFlat, an antibacterial product that provides protection against infections associated with implanted pacemakers and defibrillators. TyRx Pharma, Inc. was formerly known as Advanced Materials Design, LLC. The company was founded in 1997 and is based in Monmouth Junction, New Jersey. | $20M / Dec 08, 2010 | ||
| CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for thetreatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina. | $13M / Series C / Aug 13, 2010 | ||
| CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $34.5M / Series D / May 17, 2010 | ||
| See all 12 investments → | |||
Co-Investors
About Pappas Ventures
Pappas Ventures provides investment in the life sciences sector.
Pappas Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eric W. Linsley
Partner
|
|||
Ford Worthy
Partner
|
|||
Franz Humer
Venture partner and Senior editor
|
|||
Mike Grey
Venture Partner
|
|||
|
Artthur M. Pappas
Founder, CEO & Managing General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
112,472 investors
Health Care Investors
47,147 investors
Marketplace Investors
46,277 investors
Consumer Investors
36,317 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Fashion Investors
7,855 investors
SaaS VC Funds
69,112 investors
Health Care VC Funds
35,356 investors
FAQ
What does Artthur M. Pappas invest in?
Artthur M. Pappas invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Artthur M. Pappas?
Public channels for Artthur M. Pappas include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Artthur M. Pappas last invest?
The most recent investment recorded for Artthur M. Pappas closed in Apr 2015. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
